Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

MBX Biosciences (MBX) Total Non-Current Liabilities (2023 - 2026)

MBX Biosciences has reported Total Non-Current Liabilities over the past 4 years, most recently at $14.9 million for Q1 2026.

  • Quarterly results put Total Non-Current Liabilities at $14.9 million for Q1 2026, up 42.58% from a year ago — trailing twelve months through Mar 2026 was $14.9 million (up 42.58% YoY), and the annual figure for FY2025 was $15.9 million, up 44.05%.
  • Total Non-Current Liabilities reached $14.9 million in Q1 2026 per MBX's latest filing, down from $15.9 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $15.9 million in Q4 2025 and bottomed at $4.1 million in Q4 2023.
  • Median Total Non-Current Liabilities over the past 4 years was $11.7 million (2024), compared with a mean of $11.5 million.
  • The largest annual shift saw Total Non-Current Liabilities surged 169.73% in 2024 before it increased 14.29% in 2025.
  • Over 4 years, Total Non-Current Liabilities stood at $4.1 million in 2023, then skyrocketed by 169.73% to $11.1 million in 2024, then soared by 44.05% to $15.9 million in 2025, then dropped by 6.12% to $14.9 million in 2026.
  • Business Quant data shows Total Non-Current Liabilities for MBX at $14.9 million in Q1 2026, $15.9 million in Q4 2025, and $12.5 million in Q3 2025.